KR930005621A - 고혈압 치료용 제약 조성물 - Google Patents
고혈압 치료용 제약 조성물 Download PDFInfo
- Publication number
- KR930005621A KR930005621A KR1019920017395A KR920017395A KR930005621A KR 930005621 A KR930005621 A KR 930005621A KR 1019920017395 A KR1019920017395 A KR 1019920017395A KR 920017395 A KR920017395 A KR 920017395A KR 930005621 A KR930005621 A KR 930005621A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- compound
- configuration
- carbon atom
- treating hypertension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Removal Of Specific Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
본 발명은 특정 티아졸리딘-2,4-디온을 함유하는 고혈압 치료용 제약 조성물에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (4)
- 혈압 저하 유효량의 하기 일반식(Ⅰ)의 화합물, 제약상 허용되는 그의 양이온 염 또는 제약상 허용되는 그의 산 부가염 및 제약상 허용되는 담체로 이루어진 고혈압 치료용 제약 조성물.상기식에서, X는 C=0 또는 CH0H이다.
- 제1항에 있어서, X가 C=O인 제약 조성물.
- 제1항에 있어서, X가 CHOH이고 X의 탄소 원자가(R)배열을 가지며, 화합물이 X의 탄소원자가(S)배열을 갖는 대응하는 에난티오머로부터 실질적으로 유리된 화합물인 제약 조성물.
- 제1항에 있어서, X가 CHOH이고 X의 탄소 원자가(R)배열을 가지며, 화합물이 X의 탄소원자(R)배열을 갖는 대응하는 에난티오머로부터 실질적으로 유리된 화합물인 제약 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/765,643 US5175179A (en) | 1991-09-25 | 1991-09-25 | Method for treating hypertension |
| US765,643 | 1991-09-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930005621A true KR930005621A (ko) | 1993-04-20 |
| KR950013756B1 KR950013756B1 (ko) | 1995-11-15 |
Family
ID=25074097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019920017395A KR950013756B1 (ko) | 1991-09-25 | 1992-09-24 | 고혈압 치료용 제약 조성물 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5175179A (ko) |
| EP (1) | EP0534655B1 (ko) |
| JP (1) | JPH05194220A (ko) |
| KR (1) | KR950013756B1 (ko) |
| AT (1) | ATE124259T1 (ko) |
| AU (1) | AU644545B2 (ko) |
| CA (1) | CA2078901A1 (ko) |
| DE (1) | DE69203194T2 (ko) |
| DK (1) | DK0534655T3 (ko) |
| ES (1) | ES2073871T3 (ko) |
| HU (1) | HUT65276A (ko) |
| IL (1) | IL103202A0 (ko) |
| MX (1) | MX9205408A (ko) |
| MY (1) | MY129918A (ko) |
| NZ (1) | NZ244474A (ko) |
| TW (1) | TW209167B (ko) |
| ZA (1) | ZA927307B (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| EP1786814B1 (en) * | 2004-08-25 | 2010-03-31 | Actelion Pharmaceuticals Ltd. | Bicyclononene derivatives as renin inhibitors |
| CA2608212A1 (en) * | 2005-05-27 | 2006-12-07 | Actelion Pharmaceuticals Ltd | Novel piperidine carboxylic acid amide derivatives |
| EP1994026A2 (en) * | 2006-03-08 | 2008-11-26 | Actelion Pharmaceuticals Ltd. | New amines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX15171A (es) * | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
| GB8919417D0 (en) * | 1989-08-25 | 1989-10-11 | Beecham Group Plc | Novel compounds |
| US5053420A (en) * | 1989-10-13 | 1991-10-01 | Pershadsingh Harrihar A | Thiazolidine derivatives for the treatment of hypertension |
| US5036079A (en) * | 1989-12-07 | 1991-07-30 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
| JP2826379B2 (ja) * | 1990-01-22 | 1998-11-18 | 三共株式会社 | チアゾリジン誘導体を有効成分とする肥満性高血圧症治療剤 |
| WO1991012003A1 (en) * | 1990-02-09 | 1991-08-22 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
-
1991
- 1991-09-25 US US07/765,643 patent/US5175179A/en not_active Expired - Fee Related
-
1992
- 1992-07-29 TW TW081106014A patent/TW209167B/zh active
- 1992-09-02 JP JP4234742A patent/JPH05194220A/ja active Pending
- 1992-09-14 DK DK92308333.1T patent/DK0534655T3/da active
- 1992-09-14 EP EP92308333A patent/EP0534655B1/en not_active Expired - Lifetime
- 1992-09-14 ES ES92308333T patent/ES2073871T3/es not_active Expired - Lifetime
- 1992-09-14 DE DE69203194T patent/DE69203194T2/de not_active Expired - Fee Related
- 1992-09-14 AT AT92308333T patent/ATE124259T1/de not_active IP Right Cessation
- 1992-09-17 IL IL103202A patent/IL103202A0/xx unknown
- 1992-09-23 MY MYPI92001700A patent/MY129918A/en unknown
- 1992-09-23 CA CA002078901A patent/CA2078901A1/en not_active Abandoned
- 1992-09-23 MX MX9205408A patent/MX9205408A/es unknown
- 1992-09-23 AU AU25326/92A patent/AU644545B2/en not_active Ceased
- 1992-09-24 HU HU9203052A patent/HUT65276A/hu unknown
- 1992-09-24 ZA ZA927307A patent/ZA927307B/xx unknown
- 1992-09-24 NZ NZ244474A patent/NZ244474A/en unknown
- 1992-09-24 KR KR1019920017395A patent/KR950013756B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2073871T3 (es) | 1995-08-16 |
| MX9205408A (es) | 1993-03-01 |
| ATE124259T1 (de) | 1995-07-15 |
| DE69203194T2 (de) | 1995-11-02 |
| ZA927307B (en) | 1994-03-24 |
| IL103202A0 (en) | 1993-02-21 |
| MY129918A (en) | 2007-05-31 |
| NZ244474A (en) | 1994-01-26 |
| HUT65276A (en) | 1994-05-02 |
| AU644545B2 (en) | 1993-12-09 |
| DK0534655T3 (da) | 1995-08-28 |
| CA2078901A1 (en) | 1993-03-26 |
| DE69203194D1 (de) | 1995-08-03 |
| JPH05194220A (ja) | 1993-08-03 |
| EP0534655B1 (en) | 1995-06-28 |
| EP0534655A1 (en) | 1993-03-31 |
| KR950013756B1 (ko) | 1995-11-15 |
| HU9203052D0 (en) | 1992-12-28 |
| TW209167B (ko) | 1993-07-11 |
| US5175179A (en) | 1992-12-29 |
| AU2532692A (en) | 1993-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920018029A (ko) | 신규한 카복실산 아미드 | |
| KR880006206A (ko) | 퀴나졸리논 유도체 및 이의 제조방법 | |
| KR880002834A (ko) | α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도 | |
| KR890016966A (ko) | 신규 항바이러스제 | |
| KR960007592A (ko) | 신규한 피롤로카바졸 | |
| ES514267A0 (es) | "un procedimiento para la preparacion de derivados de pirrolidina". | |
| KR950016722A (ko) | Ldl 산화 및 죽상동맥경화증의 억제 방법 | |
| ES2051834T3 (es) | El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad. | |
| KR910019620A (ko) | 15-케토-프로스타글란딘 화합물을 사용한 췌장 질병의 치료 | |
| KR910004191A (ko) | 신질환치료제 | |
| KR920007995A (ko) | 벤즈아미드 유도체 | |
| KR930005621A (ko) | 고혈압 치료용 제약 조성물 | |
| KR950013509A (ko) | 비동기화 장애의 치료에 유용한 멜라토닌 유도체 | |
| KR880013927A (ko) | 피리미딘 유도체 | |
| KR890008136A (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로 마이신 A 유도체 | |
| KR880007070A (ko) | 백내장 치료용 약학 조성물 | |
| KR880007494A (ko) | 5-아릴-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그들의 용도 | |
| KR890008148A (ko) | 새로운 세파로스포린 화합물 및 항균제 | |
| FR2726271B1 (fr) | Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole | |
| KR900018128A (ko) | 카르복스아미드 유도체 | |
| KR940018351A (ko) | 노나테트라에노산 유도체 | |
| KR880004810A (ko) | 소화성 궤양 치료제 | |
| KR900701262A (ko) | 췌장염 등에 대한 치료제 | |
| KR960703843A (ko) | 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient) | |
| PT855398E (pt) | Derivados sasquiterpeno tendo actividade antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| NORF | Unpaid initial registration fee |